Center for Public Integrity Report, April 2007

• April 1, 2007. Asif Ismael. Report for the Center for Public Inegrity. Spending on Lobbying Thrives - Drug and health products industries invest $182 million to influence legislation.
• April 1, 2007. 60 Minutes exclusive on the report (both text and video). Under The Influence - Steve Kroft Reports On Drug Lobbyists' Role in Passing Bill That Keeps Drug Prices High.
• April, 1, 2007. PhRMA response to the report. PhRMA Member Companies Help Advance Public Health.
• News stories:
  • April 11, 2007. Anna Lewcock for In-PharmaTechnologist.com. Drug makers shell out $155m to sway legislation.
  • April 3, 2007. Bloomberg News. Record spent by drug lobby on Medicare.
  • April 3, 2007. Ricardo Alonso-Zaldivar for the Los Angeles Times. Drug lobby pays big bucks for access.

• Top 20 Congressional Recipients of Pharmaceutical campaign contributions in the 2002 Election Cycle
• Long-term contribution trends of the pharmaceutical Industry. From 2002 to present.
• December 15, 2004. Tauzin Raised Six-Figure Sum from Drug Makers - The new head of PhRMA enjoyed the financial support of pharmaceutical manufacturers while in Congress.
• July 24, 2003. Steven Weiss. Contributions correlate with outcome of drug reimportation vote.
• July 9, 2003. Sheryl Fred. How the biotech industry captured Washington's attention in 10 short years.
• November 27, 2001. Money in Politics Alert. Drug Money: The Pharmaceutical Industry's Post-Sept. 11th Lobbying.
• September 1, 2000. Prescription Drugs.
• Lobbyist Spending: Pharmaceuticals/Health Products (1998)
• Top ten pharmaceutical companies and industry groups-ranked by lobbying expenditures (1998).

Documents from Public Citizen

• December 21, 2004. Report The Bush Administration’s Drug Importation Task Force Delivers Another Favor for the Prescription Drug Industry. Also, see the press release.
• September 20, 2004. Press release. PhRMA Appears to Have Funneled Up to $41 Million To “Stealth PACs” to Help Elect a Drug Industry-Friendly Congress.
• June 23, 2004. Press release. Drug Industry and HMOs Deployed an Army of Nearly 1,000 Lobbyists to Push Medicare Bill, Report Finds.
• June 23, 2003. The Other Drug War 2003: Drug Companies Deploy an Army of 675 Lobbyists to Protect Profits.
  • Full Report.
  • Press Release.
• July 23, 2001. The Other Drug War: Big Pharma’s 625 Washington Lobbyists.
• July 2000, Public Citizen's Congress Watch, Addicting Congress Drug Companies' Campaign Cash & Lobbying Expenses
• June 26, 2000. Prove It Isn't So, Sen. Ashcroft After Taking $50,000 from Schering-Plough, Voters Need Action to Prove Missouri's Junior Senator Isn't Captured By Special Interests
• January 26, 2000. PhRMA’s Secret Playbook: "Insider" Documents Show Prescription Drug Industry Continues Campaign to Undermine Support for a Prescription Drug Benefit.
• September 30, 1999. Schering-Plough Plows Ahead with High-Priced Lobbying Campaign for a Claritin Patent Extension .
• July 29, 1999. Can Schering-Plough's Aggressive Lobbying Buy a Claritin Patent Extension?

• Pushing Prescriptions: How the Drug Industry Sells Its Agenda at Your Expense - This website is a project of the Center for Public Integrity.
• www.electionsnotauctions.org - This website is a project of the Corporations, Health Care and Democracy Initiative focused on the pharmaceutical industry.

• July 7, 2006. M. Asif Ismail for the Center for Public Integrity. Drug Lobby Second to None - How the pharmaceutical industry gets its way in Washington.
• December 14, 2004. PhRMA press release. PhRMA Names Tauzin President, CEO.
• July 15, 2004. Institute for Public Accuracy. Top Bush Administration Member on HIV-AIDS Policy Also Heads Drug Industry Front Group Opposing Generics.
• June 22, 2004. Biotechnology Industry Organization press release. BIO Announces New Food and Ag Executive Director.
• September 29, 2003. Joint statement from Health GAP, the Global AIDS Alliance, Africa Action, and the Student Global AIDS Campaign. AIDS Organizations Raise Grave Concerns in Anticipation of Ex-Pharma CEO's Confirmation As Head of Bush AIDS Plan.
• July 11, 2003. Talking points used by Big Pharma in killing the Kennedy Amendment to HR 1298. HR 1298, the U.S. Leadership Against HIV/AIDS, Tuberculosis and Malaria Act, authorized funds for the purchase of medicines. The Kennedy amendment would have directed the spending on medicines to low-cost generics.
• March 27, 2003. Corporate Council on Africa. Coalition of Non-Profits and Businesses to Lobby for President's AIDS Relief Plan for Africa.
• March 11, 2003. USTR press release. USTR Announces Personnel Appointments.
• February, 2003. American Association of Retired People. Drug Industry Finances Nonprofit Groups That Claim to Speak for Older Americans.
• July 13, 2001. Departments of Commerce, Justice, and State, the Judiciary and Related Agencies Apporpriations Bill, FY2002. Report 107-139. This is a long document. In the middle of it, it mentions a $1,000,000 appropriation to the International Intellectual Property Institute, run by former PTO Cheif Bruce Lehman.
• June 6, 2001. IFPMA press release. IFPMA and World Bank Fellowship Appointment.
• Money Watch, October 6, 1999, The FLO of Money.

• July 7, 2006. Medical News Today. Pharmaceutical Industry Spent $800M on Lobbying Over 7 Years, Report States, USA.?
• January 3, 2005. Editorial in Newsday. Tauzin Changes Sides.
• December 16, 2004. Robert Pear for the New York Times. House's Author of Drug Benefit Joins Lobbyists.
• December 16, 2004. Judy Sarasohn for the Washington Post. Tauzin to Head Drug Trade Group.
• December 15, 2004. Rueters. Drug Lobby Group Taps Tauzin for Top Job.
• November 4, 2004. Scrip. IFPMA to Reform its Structure to Imporive Lobbying Efforts.
• July 28, 2003. Donald McNeil for the New York Times. From Eli Lilly to Front Line.
• February 9, 2004. Janet Hook for the L.A. Times. Lobbyist Offers Make Jaws Drop - When drug and movie industries try to recruit a top congressman, it's a murky area for ethics.
• July 23, 2003. Jim VandeHei and Juliet Eilperin for the Washington Post. Drug Firms Gain Church Group's Aid.
• July 2, 2003. Amy Goldstein and David Brown for the Washington Post. Bush to Name Ex-Lilly CEO to Run AIDS Fund.
• June 19, 2003. Jim Lobe for One World News. U.S. Conservatives Take Aim at NGOs.
• June 9, 2003. Editorial in the Washington Post. Behind the Lobbying Curtain.
• June 1, 2003. Robert Pear for the New York Times. Drug Companies Increase Spending to Lobby Congress and Governments.
• May 1, 2003. Jim VandeHei for the Washington Post. Drug Firms Boost Bush's AIDS Plan.
• April 15, 2003. Richard Morin and Claudia Deane for the Washington Post. For CSIS, It's OSI to the Rescue.
• April 8, 2003. Richard Morin and Claudia Deane for the Washington Post. Irked Drug Industry May Pull Tank Funds.
• February 20, 2003. Bloomberg news. Health Care Industry Spends the Most on U.S. Lobbying.
• February 13, 2003. Don Michak for the Journal Inquirer. Pandering or protection? Johnson says Connecticut jobs behind drug-patent support; critics say she's repaying drug companies for re-election support.
• February 6, 2003. Tom Hamburger for the Wall Street Journal. Campaign Funds Help Steer U.S. Stance on Drug Patents: After Aiding Republicans, Drug Companies Prevail on Limiting Drugs to Poor Nations.
• February 10, 2003. Op-ed in Science by Daniel S. Greenberg. A No-Show In Politics.
• January 16, 2003. Robert Cohen and Ed Silverman Newhouse News Service. Drug Firms in Position to Cash Political Chips.
• December 9, 2002. The Washington Post. Bush Picks CXS Corp. Cheif for Treasury.
• December 5, 2002. Associated Press. About $1 Billion Was Spent on Political Ads in Midterm Elections; Group Backed by Drug Cos. in Lead.
• November 29, 2002. Maureen Groppe for the Indianapolis Star. Lilly, Other Drug Firms Find Friends in This Year's Congress.
• November 4, 2002. Greg Hitt for the Wall Street Journal. Drug Makers Pour Ad Money Into Final Days of Campaign.
• October 22, 2002. Thomas Edsall for the Washington Post. Drug Industry Financing Fuels Pro-GOP TV Spots.
• October 21, 2002. Merrill Goozner forthe American Prospect. Drug Money: How PhRMA's front groups buy elections.
• October 20, 2002. Robin Toner for the New York Times. Democrats See a Stealthy Drive By Drug Industry to Help Republicans.
• October 1, 2002. Peter Stone for the National Journal. PhRMA Writes A Big Check to the NRCC.
• August 23, 2002. Melody Petersen for the New York Times. CNN to Reveal When Guests Promote Drugs for Companies.
• November 4, 2001. Leslie Wayne and Melody Petersen for the New York Times. A Muscular Lobby Tries to Shape Nation's Bioterror Plan.
• August 14, 2001. Jennifer Washburn for the American Prospect. Undue Influence.
• July 20, 2001. Associated Press. Rove's ties to pharmaceutical industry probed.
• April 9, 2001. Mike Allen in the Washington Post. Gay Republican to Hold AIDS Post.
• February 13, 2001. Julian Borger form The Guardain. Industry that stalks the US corridors of power
• January 27, 2001. Fred Charatan, British Medical Journal. U.S. Companies Help Pay for Bush Inauguration
• June 26, 2000, Paul Kane, in Roll Call, Hatch Admits He's 'Senator Anonymous'
• June 24, 2000, Jackie Judd and Carter M. Yang, in ABC News, `Senator Anonymous' Revealed
• Multinational Monitor, May 1996, Revolving Doors

  Dennis DeConcini, a member of the S&L scandal's Keating Five gang, chaired a Senate committee that oversaw drug patents until retiring last year. He swiftly moved to Parry & Romani Associates, a firm run by his former chief of staff, Romano Romani.

  At his new home, DeConcini represents pharmaceutical makers like Pfizer, Genetech, Upjohn and Glaxo-Wellcome, the world's largest drug company. Glaxo-Wellcome hired Parry & Romani to maintain a loophole in the GATT trade treaty that extends patents on drugs such as Glaxo's Zantac [see "GATT Rx: Profit Overdose," Multinational Monitor, May 1995]. The loophole, which remains unclosed, is worth millions to DeConcini's client because it prevents consumers from buying cheaper generic alternatives to Zantac for another two years.